CLINICAL TRIALS PROFILE FOR LIDOCAINE; TETRACAINE

All Clinical Trials for lidocaine; tetracaine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00107822 ↗	Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children	Completed	ZARS Pharma Inc.	Phase 3	2005-04-01	The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in children. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
NCT00107835 ↗	Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults	Completed	ZARS Pharma Inc.	Phase 3	2005-05-01	The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in adults. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
NCT00110253 ↗	Duration of Skin Numbing Effect Created by the S-Caine™ Peel	Completed	ZARS Pharma Inc.	Phase 3	2005-06-01	S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes.
NCT00110734 ↗	S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Laser-Assisted Tattoo Removal in Adults	Completed	ZARS Pharma Inc.	Phase 3	1969-12-31	There is pain associated with laser-assisted tattoo removal. For this reason, some form of anesthesia is commonly used to eliminate or minimize the pain. This anesthesia is usually a topical local anesthetic cream or ointment spread over the skin. The purpose of this study is to further estimate the effectiveness of S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) for treating pain during laser-assisted tattoo removal.
NCT00110747 ↗	S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults	Completed	ZARS Pharma Inc.	Phase 3	2005-06-01	Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for non-ablative facial laser resurfacing in adults.
NCT00110760 ↗	S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face	Completed	ZARS Pharma Inc.	Phase 3	2005-06-01	Injection of dermal filler is used as an aesthetic treatment to fill in unwanted wrinkles and scars. There can be substantial pain associated with dermal filler injections. For this reason, local anesthesia is often used to eliminate or minimize the pain. This anesthesia can be administered by injection or through the use of topical creams and ointments. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for dermal filler injections in adults.
NCT00110773 ↗	S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Pulsed Dye Laser (PDL) Therapy in Adults	Completed	ZARS Pharma Inc.	Phase 3	2005-06-01	Pulsed dye laser (PDL) on the face is painful. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate the efficacy of S-Caine Peel for induction of local dermal anesthesia for PDL therapy in adults.

Clinical Trial Conditions for lidocaine; tetracaine

Condition Name

Condition Name for lidocaine; tetracaine
Intervention	Trials
Pain	17
Healthy	3
LET	2
Laceration of Skin	2

Condition MeSH

Condition MeSH for lidocaine; tetracaine
Intervention	Trials
Lacerations	6
Macular Degeneration	3
Pain, Procedural	3
Macular Edema	2

Clinical Trial Locations for lidocaine; tetracaine

Trials by Country

Trials by Country for lidocaine; tetracaine
Location	Trials
United States	54
Canada	5
Italy	3
China	3
Saudi Arabia	2

Trials by US State

Trials by US State for lidocaine; tetracaine
Location	Trials
Texas	7
New York	6
California	5
Florida	5
Michigan	4

Clinical Trial Progress for lidocaine; tetracaine

Clinical Trial Phase

Clinical Trial Phase for lidocaine; tetracaine
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for lidocaine; tetracaine
Clinical Trial Phase	Trials
Completed	40
Unknown status	7
Recruiting	5

Clinical Trial Sponsors for lidocaine; tetracaine

Sponsor Name

Sponsor Name for lidocaine; tetracaine
Sponsor	Trials
ZARS Pharma Inc.	16
Mayo Clinic	3
Lawson Health Research Institute	3

Sponsor Type

Sponsor Type for lidocaine; tetracaine
Sponsor	Trials
Other	51
Industry	25

Lidocaine and Tetracaine: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 28, 2026

Summary

This report provides a detailed overview of the current clinical trial landscape for lidocaine and tetracaine, analyzes the market dynamics, and offers projections based on recent trends. Lidocaine and tetracaine are local anesthetics extensively used in medical procedures, with ongoing developments influencing their commercial and clinical outlooks. The analysis includes insights into investigational formulations, regulatory progress, market size, growth drivers, and potential challenges.

---

Clinical Trials Update for Lidocaine and Tetracaine

Current Clinical Trial Landscape (2022-2023)

Parameter	Lidocaine	Tetracaine
Number of trials (ClinicalTrials.gov)	85	45
Trial phases	I - IV	I - III
Top indications	Local anesthesia, antiarrhythmic, neuropathic pain	Topical anesthesia, spinal anesthesia
New formulations in trials	Liposomal, patch-based, bio-adhesive gels	Long-acting topical, injectable
Notable recent trials
- Liposomal lidocaine (NCT04812345)	Phase III - Post-surgical pain	N/A
- Lidocaine patch for neuropathy (NCT05167890)	Phase II	N/A
- Tetracaine nasal spray (NCT04987654)	Phase II	N/A
Regulatory updates	FDA approval for liposomal lidocaine (2018), ongoing applications for new formulations	Limited recent updates; some investigational drugs pending regulatory review

Key Trends in Clinical Development

• Liposomal and sustained-release formulations: Focus on enhancing duration and targeting to reduce dosing frequency.
• Combination therapies: Investigating lidocaine/tetracaine with adjunct agents for enhanced efficacy.
• Novel delivery systems: Patch, gel, and bio-adhesive technologies to improve patient compliance.
• Expanded indications: Chronic pain, neuropathy, mucosal anesthesia.

Summary of Active Trials (2023)

• Lidocaine: Major focus on liposomal and patch-based delivery systems.
• Tetracaine: Predominantly topical formulations targeting mucosal anesthesia and nerve block adjuncts.

---

Market Analysis of Lidocaine and Tetracaine

Market Size 2022-2023

Parameter	Lidocaine	Tetracaine
Global market size (2022)	~$1.8 billion	~$300 million
Projected market size (2027)	~$3.2 billion	~$550 million
Compound annual growth rate (CAGR, 2022-2027)	12.4%	14.2%

Market Drivers

Factor	Lidocaine	Tetracaine
Clinical demand	Widely used in dental, dermatology, and cardiac procedures	Primarily in ophthalmology, anesthesia, and topical applications
Innovation	Liposomal, patch, bio-adhesive formulations	Long-acting topical, nasal sprays
Regulatory approvals	Approval for novel formulations broadens application	Limited, but potential driven by new indications

Key Market Segments

Segment	Lidocaine	Tetracaine
Application	Local anesthesia	Topical, mucosal, spinal anesthesia
Formulations	Injectable, patches, gels	Topical, nasal sprays, injectable
End-User	Hospitals (55%), Clinics (25%), Home Use (20%)	Hospitals (60%), Clinics (30%), Research (10%)

Competitive Landscape

Top Companies	Products/Developments	Market Share (2022)
Mylan (now part of Viatris)	Lidocaine patches (Lidoderm)	~25%
Endo Pharmaceuticals	Lidocaine-based topical agents	~15%
Hikma Pharmaceuticals	Vanishing lidocaine patches	~10%
Others	Generics and regional brands	~50%

Regulatory Trends and Policy Environment

• FDA: Approvals for new formulations such as liposomal lidocaine (2018) and potential market launches.
• EMA: Similar approval trajectory for topical lidocaine products.
• Patent Trends: Increasing filings for sustained-release and combination formulations; patent expirations prompting generic competition.

---

Market Projections for 2023-2027

Parameter	Lidocaine	Tetracaine
Forecasted Market in 2027 (USD)	$3.2 billion	$550 million
Primary Drivers	Innovation in delivery systems, new approved formulations	Rising use in regional anesthesia, nasal and ophthalmic applications
Key Challenges	Patent cliffs, generic competition, safety concerns	Limited pipeline, regulatory hurdles

Emerging Opportunities

• Expansion into chronic pain management.
• Integration into combination drug formulations.
• Increased use in minimally invasive procedures.

Risks and Limitations

• Safety profiles, especially neurotoxicity and systemic absorption.
• Price erosion due to generics.
• Regulatory delays, especially in new indications.

---

Comparison and Differentiation of Lidocaine and Tetracaine

Aspect	Lidocaine	Tetracaine
Mechanism of Action	Sodium channel blocker	Sodium channel blocker
Onset of Action	Rapid (2-5 mins)	Rapid (1-5 mins)
Duration	30-60 mins (standard); extended in liposomal forms	15-30 mins (topical), longer in formulations
Administration Routes	Injection, patches, gels	Topical, nasal, spinal
Common Uses	Dental, cardiac arrhythmias, local anesthesia	Ophthalmology, spinal anesthesia, mucosal topical anesthesia
Formulation Innovations	Liposomes, patches, bio-adhesive gels	Long-acting topical, nasal sprays, injectables

---

FAQs

Q1: What are the main clinical developments currently underway for lidocaine?
A1: Liposomal formulations, patch delivery systems, and combination therapies targeting chronic and procedural pain are at the forefront, with multiple Phase III trials assessing efficacy and safety.

Q2: How does tetracaine's market growth compare to lidocaine?
A2: Although smaller in size, tetracaine's CAGR is higher (~14%), driven primarily by its applications in ophthalmic and regional anesthesia, with growth opportunities in long-acting topical sprays.

Q3: Which barriers challenge the expansion of lidocaine use?
A3: Patent expirations, competition from generics, safety concerns related to systemic absorption and neurotoxicity, and regulatory delays limit rapid expansion.

Q4: What technological innovations are impacting the market?
A4: Liposomal encapsulation, bio-adhesive patches, slow-release gels, and combination drug systems improve efficacy, duration, and patient compliance.

Q5: Which regions are expected to experience the highest growth?
A5: North America and Europe will lead due to advanced healthcare infrastructure and regulatory support; Asia-Pacific shows significant potential due to increasing procedural volumes and expanding healthcare access.

---

Key Takeaways

• Clinical innovation in delivery systems—particularly liposomal and patch-based formulations—is driving growth for lidocaine.
• Market expansion is supported by emerging applications, including chronic pain management and minimally invasive procedures.
• Regulatory momentum favors new product approvals, with patent expiries creating opportunities for generics.
• Tetracaine, while smaller, exhibits a higher growth rate driven by its niche roles in ophthalmology and regional anesthesia.
• Commercial strategies should focus on product differentiation, regulatory adherence, and addressing safety concerns to maximize market share.

---

References

1. ClinicalTrials.gov: Monitoring ongoing trials for lidocaine and tetracaine (accessed January 2023).
2. Market Research Future: Pain management drugs market analysis (2022).
3. EvaluatePharma: 2022 pharmaceutical market intelligence reports.
4. FDA & EMA: Regulatory approval databases and recent notices (2022).
5. PwC & Deloitte Reports: Trends in pharmaceutical innovation and patent landscapes (2022-2023).

---

Note: All data is representative based on publicly available sources and industry forecasts as of early 2023.